Examkin

Soru

Zorluk: KolayInfectious Diseases

A 42-year-old woman is evaluated on the medical floor for ongoing management of a bloodstream infection. She was admitted three days ago with a high fever and localized erythema surrounding a peripheral intravenous catheter site. Blood cultures were drawn, the catheter was removed, and she was started on empiric intravenous vancomycin and intravenous cefepime. The patient is currently afebrile and her localized erythema has resolved. Today, the initial blood cultures are finalized, showing growth of Staphylococcus aureus. Susceptibility testing reveals the organism is resistant to penicillin but susceptible to oxacillin, cefazolin, and vancomycin. Repeat blood cultures drawn 48 hours after admission show no growth. Which of the following is the most appropriate next step in the antibiotic management of this patient?

  1. Discontinue current antibiotics and initiate intravenous cefazolinCevap
  2. B
    Discontinue cefepime and continue intravenous vancomycin
  3. C
    Discontinue vancomycin and continue intravenous cefepime
  4. D
    Discontinue current antibiotics and prescribe oral linezolid
  5. E
    Continue current antibiotics and add intravenous gentamicin

Cevap

The most appropriate step is to discontinue the broad-spectrum empiric regimen (vancomycin and cefepime) and initiate targeted therapy with intravenous cefazolin for methicillin-susceptible Staphylococcus aureus (MSSA).
The correct action is to narrow the antibiotic spectrum to intravenous cefazolin. The patient has confirmed methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia. For MSSA bloodstream infections, targeted beta-lactam therapy (such as cefazolin, nafcillin, or oxacillin) is the standard of care and is clinically superior to vancomycin, demonstrating faster bacterial clearance and lower mortality rates. Transitioning to targeted therapy also aligns with core antibiotic stewardship principles.

Adım Adım Çözüm

1
Interpret the culture and susceptibility results.
The pathogen is Staphylococcus aureus susceptible to oxacillin, confirming it is methicillin-susceptible (MSSA).
Proper identification of the organism and its resistance profile is required to transition from empiric to definitive therapy.
2
Evaluate the current empiric antibiotic regimen.
The patient is on vancomycin (covering MRSA) and cefepime (covering Pseudomonas and other gram-negatives), which is overly broad for isolated MSSA.
Prolonged use of unnecessarily broad antibiotics drives resistance and increases the risk of adverse drug events.
3
Select the optimal definitive therapy for MSSA bacteremia.
Intravenous cefazolin (or an anti-staphylococcal penicillin like nafcillin) is chosen over vancomycin.
Clinical evidence consistently demonstrates that beta-lactams are superior to vancomycin for treating MSSA bacteremia, leading to improved survival and lower clinical failure rates.

Anahtar Kavram

Definitive antibiotic management of methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia requires de-escalation to an intravenous anti-staphylococcal beta-lactam (e.g., cefazolin or nafcillin), as these agents are superior to vancomycin.
Bu soruyu puanla

Konular

Infectious Diseases

Bu konudan daha fazla soru